CoreRx, Inc., a leading player in the pharmaceutical contract development and manufacturing industry, is headquartered in the United States. Founded in 2010, the company has established itself as a trusted partner for pharmaceutical and biotechnology firms, specialising in the development and production of complex drug formulations. With a focus on oral solid dosage forms, CoreRx offers a range of services, including formulation development, analytical testing, and commercial manufacturing. Their commitment to innovation and quality has positioned them as a preferred choice for clients seeking tailored solutions in drug development. CoreRx's notable achievements include a robust portfolio of successful product launches and a reputation for excellence in regulatory compliance, making them a key contributor to the advancement of healthcare solutions globally.
How does CoreRx, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
CoreRx, Inc.'s score of 17 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
CoreRx, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that CoreRx, Inc. may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, it will be essential for CoreRx, Inc. to consider developing and communicating its climate commitments to align with broader environmental goals.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CoreRx, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
